FIELD: medicine.
SUBSTANCE: invention refers to Trecresan applications as an acid lipase activator.
EFFECT: invention enables extending the range of cholesterol-lowering drugs.
2 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT TO DECREASE CHOLESTEROL ESTERASE ACTIVITY | 2010 |
|
RU2444357C1 |
AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
TRECRESAN APPLICATION FOR TREATING PATIENTS SUFFERING ARTERIAL HYPERTENSION AND OBESITY | 2010 |
|
RU2429832C1 |
MEDICATION MODULATING CONCENTRATION OF FERRITIN IN BLOOD SERUM | 2012 |
|
RU2486895C1 |
USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND BIS-(2-METHYLPHENOXY-ACETATE) ZINC (ZINCATRAN) FOR REDUCING TOTAL ACTIVITY OF ACIDIC PHOSPHOLIPASE A1 | 2014 |
|
RU2545888C1 |
MEDIATION INCREASING LEVEL OF LACTOFERRIN IN ORGANISM | 2012 |
|
RU2486894C1 |
METHOD OF PATIENTS WITH OBESITY AND ARTERIAL HYPERTENSION STATE CORRECTION | 2019 |
|
RU2729352C1 |
USING PROTATRAN 4-CHLOR-2-METHYLPHENOXYACETATE (CHLORCRESACIN) FOR ARREST OF CHOLESTEROLESTERASE ACTIVITY | 2014 |
|
RU2563831C1 |
SUBSTANCE REDUCING CHOLESTEROL ESTERASE ACTIVITY | 2014 |
|
RU2540518C1 |
AGENT STIMULATING EXPRESSION OF MATRIX RNA OF TRYPTOPHANYL-tRNA-SYNTHETASE | 2010 |
|
RU2429836C1 |
Authors
Dates
2011-09-27—Published
2010-09-08—Filed